SCHEMBL5952944

SCHEMBL5952944

Cc1cn([C@@H]2C=C[C@H](CO)O2)c(=O)nc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.59
ALB P02768 4/20 0.59
ALDH1A1 P00352 2/20 0.59
BLM P54132 2/20 0.59
POLB P06746 1/20 0.59
ADRA1A P35348 1/20 0.59
MTOR P42345 2/20 0.34
DNMT1 P26358 2/20 0.34
THRB P10828 1/20 0.34
MDM2 Q00987 1/20 0.34
NCOA1 Q15788 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34
GMNN O75496 1/20 0.34
TP53 P04637 1/20 0.34
NFKB1 P19838 1/20 0.34
THPO P40225 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
HBB P68871 1/20 0.34
PMP22 Q01453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4749034 1.00 LMNA (0.59) LMNAALBALDH1A1BLMPOLB
Elvucitabine SCHEMBL1649928 0.84 ALB (0.55) LMNAALBALDH1A1BLMPOLB
Elvucitabine SCHEMBL3298257 0.84 ALB (0.55) LMNAALBALDH1A1BLMPOLB
SCHEMBL30667453 0.84 LMNA (0.46) LMNAALBALDH1A1BLMPOLB
Dexelvucitabine SCHEMBL599014 0.84 ALB (0.55) LMNAALBALDH1A1BLMPOLB
SCHEMBL4277774 0.83 ALDH1A1 (0.57) LMNAALBALDH1A1BLMPOLB
SCHEMBL9665842 0.81 ALDH1A1 (0.45) LMNAALBALDH1A1BLMPOLB
SCHEMBL5075702 0.80 LMNA (0.43) LMNAALBALDH1A1BLMPOLB
SCHEMBL9856521 0.77 POLG (0.50) POLB
SCHEMBL5821 0.76 LMNA (0.55) LMNAALBALDH1A1BLMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293668-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides SCHINAZI RAYMOND F 2008-11-27 US disclosed
US-7419966-B2 [5-carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides EMORY UNIVERSITY (US) 2008-09-02 US disclosed
US-20060217345-A1 Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293668-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides DUT, NUDT1, PNP LMNA 1598/4885ALB 1099/4885ALDH1A1 1880/4885
US-20060217345-A1 Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases NTPCR, PNP, TYMP LMNA 158/4885ALB 4041/4885ALDH1A1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.